Marcelo Antonio Sanchez Gonzalez MD, Presenter: Nothing to Disclose

Mariana Nelida Benegas Urteaga MD, Abstract Co-Author: Nothing to Disclose

Noemi Reguart MD, Abstract Co-Author: Nothing to Disclose

Daniel Barnes MD, Abstract Co-Author: Nothing to Disclose

Josep Guitart MD, Abstract Co-Author: Nothing to Disclose

Oscar Sabino Chirife Chaparro MD, Abstract Co-Author: Nothing to Disclose

Rosario Jesus Perea MD, PhD, Abstract Co-Author: Nothing to Disclose

Teresa Maria de Caralt, Abstract Co-Author: Nothing to Disclose

1. To explain alternative methods to RECIST to evaluate the therapeutic response to new molecularly targeted therapies in lung cancer. 2. To know perfusion CT as a non invasive method to evaluate tumoral angiogenesis 3. To describe the CT technique, data processing and reporting to perform a perfusion CT of pulmonary tumors.  

1. Introduction 2. Molecularly targeted therapies in lung cancer 3. Limitations of RECIST to evaluate response 4. Alternative methods a. Cavitations: Crabb diameter b. Necrosis: Choi criteria 5. Functional imaging a. Ultrasound b. PET-CT c. MRI d. Perfusion CT 6. Perfusion CT a. Perfusion CT and Angiogenesis b. Pathologic correlation c. Technique i. CT system requirements ii. Contrast administration iii. Post-processing iv. Terminology and units v. Reporting d. Drawbacks/Caveats i. Radiation exposure ii. Reproducibility iii. Standardization of procedures e. Perfusion CT and antiangiogenic treatments   7. Dual-CT to assess perfusion 8. Multifunctional profiling: PET-CT combined with perfusion CT 9. Conclusions  

http://abstract.rsna.org/uploads/2014/14014380/14014380_hpwl.pdf

Sanchez Gonzalez, M, Benegas Urteaga, M, Reguart, N, Barnes, D, Guitart, J, Chirife Chaparro, O, Perea, R, de Caralt, T, Evaluating Response to New Targeted Therapies in Lung Cancer: Functional Imaging and Perfusion CT—What Should We Know?.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14014380.html